Diversified Consumer Services
Company Overview of Baylor College of Medicine
Baylor College of Medicine is an education, research, and patient care institution that comprises neurology, neuroscience, neurosurgery, obstetrics and gynecology, ophthalmology, orthopedic Surgery, otorhinolaryngology & communicative sciences, pathology, pediatrics, pharmacology, and cardiovascular sciences, dermatology, and developmental biology departments. Baylor College of Medicine was formerly known as Baylor University College of Medicine and changed its name to Baylor College of Medicine in 1969. The institution was founded in 1900 and is based in Houston, Texas.
One Baylor Plaza
Mail Stop 160
Houston, TX 77030
Founded in 1900
Key Executives for Baylor College of Medicine
Chief Executive Officer and President
Chairman of the Department of Neurology
Compensation as of Fiscal Year 2016.
Baylor College of Medicine Key Developments
Cell Medica Expands Its Partnership with Baylor College of Medicine
Nov 10 16
Cell Medica has expanded its partnership with Baylor College of Medicine to develop an off-the-shelf allogeneic cell therapy, taking advantage of the unique aspects of invariant natural killer T (NKT) cells. Cellular immunotherapy offers great promise in treating cancer but may be limited in application if products require individual preparation for each new patient. Most cell-based immunotherapies utilize T cells which are naturally programmed to kill malignant cancer cells and can be further engineered to express chimeric antigen receptors (CARs) or modified T cell receptors to improve their use for treating cancer. As an off-the-shelf product, however, allogeneic T cells derived from healthy donors carry the risk of recognizing the patient’s body as foreign, which can cause a serious side effect called graft versus host disease (GvHD). Baylor and Cell Medica plan to overcome this problem by developing off-the-shelf therapies based on CAR-modified NKT cells generated in large volumes from healthy donors. While endowed with powerful cancer-killing properties like conventional T cells, invariant NKT cells express special T cell receptors that are not associated with GvHD. Hence allogeneic NKT cells can be used to treat multiple cancer patients with minimal risk of GvHD. The success of this program may expand significantly the potential use of cell-based immunotherapies on a cost-effective basis for the treatment of cancer patients. This new project will be conducted under the exclusive license and co-development agreement between Cell Medica and Baylor, announced in June 2016. Under the agreement, Baylor will perform the research required to develop off-the-shelf NKT cell therapies with funding and strategic input from Cell Medica. Cell Medica will have an exclusive option to develop all products and technologies arising from this effort, under the terms of the licensing agreement. As announced previously, Cell Medica and Baylor expect that their collaboration will generate a significant number of new products for Cell Medica’s pipeline.
Texas Children's and Baylor College of Medicine Receives Five-Year $7.5 Million Grant from the National Institute of Allergy and Infectious Diseases
Sep 15 16
Texas Children's and Baylor College of Medicine received a five-year, $7.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the NIH. The grant will go toward efforts to combat Clostridium difficile, a bacterium that causes diarrhea and severe inflammation of the colon. Dr. Tor Savidge, associate professor of pathology and immunology at Baylor and associate director of Texas Children's Microbiome Center, is the principal investigator for the C. diff study.
Cell Medica Announces Licensing Agreement with Baylor College of Medicine to Create Next Generation Cellular Immunotherapy Products
Jun 17 16
Cell Medica an exclusive licensing agreement and a co-development partnership with the Baylor College of Medicine to create next generation cellular immunotherapy products for the treatment of cancer. This new collaboration is expected to generate a significant number of new products for Cell Medica's cellular immunotherapy pipeline. It provides the company with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor's leading research teams in the field of genetically engineered immune cells. The collaboration will build upon the recent clinical success of advanced chimeric antigen receptors (CARs) to enable human immune cells to recognise and kill cancer cells expressing tumour associated antigens. Five product programs have been defined for the initial development plan focused on the application of CAR technology to natural killer T (NKT) cells as a novel immune cell type with biological properties that may be particularly effective for targeting solid tumours. NKT cells are known to infiltrate tissues where solid tumours arise and kill both malignant cells and cancer-enabling cells such as the tumour associated macrophages. The development plan also includes a genetically engineered T cell receptor (TCR) for use in NKT cells and T cells. Cell Medica has paid an up-front fee for the exclusive licensing arrangements and will make additional payments to exercise its exclusive option to licence future products. Baylor is eligible to receive further payments related to late stage clinical, regulatory approval and sales milestones, as well as single digit royalties for the successful development of specific products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|